The Barbara Ann Karmanos Cancer Institute, the largest provider of cancer care and research in Michigan and part of McLaren ...

Randomized Phase 2 study initiated evaluating the combination of casdozokitug, toripalimab and bevacizumab in patients with liver cancer - REDWOOD CITY, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- ...

Dan G. Duda, DMD, Ph.D., of the Edwin L. Steele Laboratories for Tumor Biology and Department of Radiation Oncology at ...

It uses electromagnetic waves to target tumors and is available to patients for whom first- and second-line treatments have ...

Liver cancer rates have more than tripled in the U.S. since 1980 and continue to rise. More than 41,000 people will be ...

Liver cancer rates have more than tripled in the U.S. since 1980 and continue to rise. More than 41,000 people will be ...

Dan G. Duda, DMD, PhD, of the Edwin L. Steele Laboratories for Tumor Biology and Department of Radiation Oncology at Massachusetts General Hospital, is the corresponding author of a paper published in ...

Liver cancer is a disease with a poor prognosis. Despite multiple therapeutic options, including the recent emergence of immunotherapy as a first-line systemic treatment, the outcomes remain poor.

Model accurately predicts hepatocellular carcinoma among patients with HCV-related cirrhosis with SVR to DAAs.

Josep M. Llovet, MD, PhD, describes the phase 3 LEAP-012 clinical study, including its methods, design, and enrollment ...

Dan G. Duda, DMD, PhD, of the Edwin L. Steele Laboratories for Tumor Biology and Department of Radiation Oncology at Massachusetts General Hospital ...

Hepatocellular carcinoma (HCC) stands as the dominant form of liver cancer, ranking as the fourth leading cause of cancer-related deaths globally.